

Image



1644

Atty. Docket No.: 11111/1210

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal
Serial No.: 09/318,870
Filed: May 26, 1999
Titled: Cytokine-Coated Cells and Methods of
Modulating an Immune Response to an
Antigen

Examiner: Belyavskyi, M

Group Art Unit: 1644

Conf. No.: 2018

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Statement of Substance; and
2. Return Post Card.

Respectfully submitted,

Date: December 3, 2003

Name: Kathleen M. Williams
Registration No.: 34,380
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel. (617) 239-0100



Atty. Docket No.: 11111/1210

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal
Serial No.: 09/318,870
Filed: May 26, 1999
Titled: Cytokine-coated cells and methods of
modulating an immune response to an
antigen

Examiner: Belyavskyi, M

Group Art Unit: 1644

Conf. No.: 2018

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE

Sir:

This Statement of Substance is being filed pursuant to Applicant's telephone interview with Examiner Belyavskyi, and Supervisor Chan on November 4, 2003.


The enablement rejection under 35 U.S.C. §112, first paragraph was discussed and agreement was not reached on the sufficiency of the enablement of the claims. With respect to the prior art rejections as set forth in the previous office action, the Examiner's position is that U.S. Patent No. 6,277,368 teaches a vaccine composition comprising a cancer cell coated with exogenous cytokine. Applicant disagreed with the Examiner, but agreed to re-evaluate the reference and submit a supplemental response.

Serial No.: 09/318,870

Page 2

Respectfully submitted,

Date: December 3, 2003



Name: Kathleen M. Williams
Registration No.: 34,380
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel. (617) 239-0100